News | April 29, 2023
RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
The business and product range of Ipca and that of Unichem complements each others business and product range
Subscribe To Our Newsletter & Stay Updated
